XML 26 R13.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Intangible Assets, Net | 12 Months Ended
--- | ---
Dec. 31, 2018
Goodwill And Intangible Assets Disclosure [Abstract] |
Intangible Assets, Net |
6. | Intangible Assets, net
Intangible assets are related to certain capitalized milestone and sublicense payments. The following table presents intangible assets (in thousands):
|  | December 31, |
|  | 2018 |  |  | 2017 |
Intangible assets |  | $ | 19,773 |  |  | $ | 2,500 |
Less accumulated amortization |  |  | (8,056 | ) |  |  | (1,194 | )
Total |  | $ | 11,717 |  |  | $ | 1,306 |
For the year ended December 31, 2018, we recorded $10.9 million in cost of sales - amortization of intangible assets which included amortization of $8.1 million, $1.5 million and $1.3 million related to capitalized milestone and sublicense payments to Merck, GlaxoSmithKline Biologicals SA (“GSK”) and Coley Pharmaceutical Group, Inc. (“Coley”), respectively. For the year ended December 31, 2017, we recorded $1.2 million in cost of sales - amortization of intangible assets related to a capitalized milestone payment to Coley. See Note 10. At December 31, 2018, the remaining intangible asset has an estimated remaining useful life of 16 months and will be fully amortized by April 2020. No impairment of intangible assets has been identified during the years presented.

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for all or part of the information related to intangible assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -URI http://asc.fasb.org/topic&trid=2144416 + Details
Name: | us-gaap_IntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration